Abstract:Daidzein (D1) has been proved to be of great benefit to human health. More and more attention was paid to the metabolic process of D1. Most studies focused on the metabolites of D1 and analogs were determined through the excretion of animals and humans by traditional HPLC-MS, while their in situ distribution and metabolism in organs in vivo has not been reported. In our group, novel daidzein sulfonate derivatives were synthesized and confirmed to have excellent pharmaceutical properties. They exhibited good anti-inflammatory, inhibitory activities on human vascular smooth muscle cell proliferation and other bioactivities. Compared with traditional analytical methods, matrix-assisted laser desorption ionization time-of-flight mass spectrometry imaging (MALDI-TOF MSI) can directly analyze the distribution of compounds in tissues and organs. In this study, we investigate the in situ distribution and metabolism of D1 and its derivatives (DD2, DD3) in the organs of mice based on MALDI-TOF MSI for the first time. Trace prototype compounds were detected in the plasma 4 h after the intravenous injection of D1, DD2, and DD3. Seven phase I metabolites and seven phase II metabolites were detected. D1 sulfates were found in the plasma and in organs except the heart. The presence of D1 and DD3 monosulfates in the brain indicated that they could penetrate the blood-brain barrier. DD2 and DD3 could be hydrolyzed into D1 and their metabolic pathways were similar to those of D1. In addition, a ligand-receptor docking of D1 and DD2 with mitogen-activated protein kinase 8 (JNK1) was performed because of their significant anti-inflammatory activities through the JNK signaling pathway. It showed that the binding energy of DD2 with JNK1 was obviously lower than that of D1 which was consistent with their anti-inflammatory activities. It provided a theoretical basis for further validation of their anti-inflammatory mechanism at the protein level. In summary, the research will provide beneficial guidance for further pharmacological, toxicological studies and the clinical-use research of these compounds.

HPLC Studies for Prodrug of Isoflavones Sulphonic Acid Ester

Pre-clinical Pharmacokinetics of Novel Soybean Iosflavone Sulfonate

Pharmacokinetics Studies of Novel Soybean Iosflavone Sulfonate in Rats with HPLC

A Lipophilic Prodrug of Danshensu: Preparation, Characterization, and in Vitro and in Vivo Evaluation

Metabolic Studies of Four Soy Isoflavones in Rats by Hplc-Hr-Ms

Preparation of Highly Pure Daidzin on Oligo-Β-cyclodextrin-sepharose HP and Investigation of Chromatographic Behavior of Isoflavones by Molecular Docking.

Preparation of inclusion complex of daidzein and hydropropyl-β- cyclodextrin

Pharmacokinetics of Daidzein 4â€²-Phenylsulfonyl Ester and Its Active Metabolite Daidzein Assayed by HPLC Method in Rats After Intravenous Administration and Oral Administration

Inhibition Activity of Novel Soybean Isoflavone Sulfonate on the Proliferation of Vascular Smooth Muscle Cells

Study on stability of daidzein in soybean during soaking processing

Studies of the Chemical Constituents of Soybean Isoflavone

Study on Pharmacological Properties and Cell Absorption Metabolism of Novel Daidzein Napsylates

Study on simultaneous determination of soy isoflavones and its metabolites in rat serum by liquid chromatography-tandem mass spectrometry

Soy Isoflavones and their Effects on Xenobiotic Metabolism

Optimal Technological Parameters of Acid Hydrolysis of Soy Isoflavone

Study on valid composition of soybean isoflavones products by HPLC

Determination the Content of the Soybean Isoflavone by RP-HPLC

Enhanced Oral Bioavailability of Daidzein by Self-Microemulsifying Drug Delivery System

Distribution and metabolism of daidzein and its benzene sulfonates in vivo (in mice) based on MALDI-TOF MSI

An HPLC method for the pharmacokinetic study of daidzein-loaded nanoparticle formulations after injection to rats.

Determination of Daidzein in Rat Plasma by LC